Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCRM
Special Issues
Hypertension in Cardiorenal Diseases
share announcement

Hypertension in Cardiorenal Diseases

A special issue of Journal of CardioRenal Medicine (ISSN 3042-6987).

Deadline for manuscript submissions: 31 October 2026 | Viewed by 1575

Special Issue Editors

Dr. Caterina Carollo

E-Mail Website
Guest Editor
Unit of Nephrology and Dialysis, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hypertension Excellence Centre, University of Palermo, 90133 Palermo, Italy
Interests: nephrology; hypertension; dialysis; nephrocardiology; cardiorenal syndromes; diabetic nephropathy
Special Issues, Collections and Topics in MDPI journals
Dr. Giuseppe Mulè

E-Mail Website
Guest Editor
Unit of Nephrology and Dialysis, Hypertension Excellence Centre, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy
Interests: hypertension; atherosclerosis; insulin resistance; echocardiography; diabetes; blood pressure; internal medicine; cardiovascular medicine; heart failure; myocardial infarction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The number of patients with or at risk for coexisting kidney and heart diseases, often named “cardiorenal” or “renocardiac” syndromes, is increasing worldwide. A lot of studies documented higher mortality and significant morbidity in these kinds of patients. The interactions between kidney and heart diseases lead to a complex pathophysiology with typical disease features, and to the need for specific treatment and specialized care that may not be adequately addressed by cardiologists or nephrologists. Moreover, in addition to new drugs, recent advances in medical technologies and devices could offer the opportunity to improve treatments. Everywhere, independent of care settings, there is an urgent, unsatisfied need to take care of patients with combined kidney and heart diseases. In such a context, hypertension plays a pivotal role, since a significant fraction of these patients, in fact, exhibits higher blood pressure.

We are pleased to invite you to contribute to the empowerment of this important field of research with original research articles and reviews. Research areas may include (but are not limited to) the following: hypertension, CKD, HF, cardiorenal syndromes, diabetes mellitus in CKD and HF, and imaging in hypertension.

We look forward to receiving your contributions.

Dr. Caterina Carollo
Dr. Giuseppe Mule
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of CardioRenal Medicine is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hypertension
  • CKD
  • HF
  • cardiorenal syndromes
  • diabetes mellitus in CKD and HF
  • imaging in hypertension

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 2546 KB  
Review
Renal Denervation: From Historical Roots to the Modern Therapeutic Paradigm
by Lauren Morrison and Alec Vishnevsky
J. CardioRenal Med. 2026, 2(2), 7; https://doi.org/10.3390/jcrm2020007 - 26 May 2026
Viewed by 82
Abstract
Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the availability of effective medications and lifestyle interventions, blood pressure control rates remain poor globally, and the prevalence of hypertension continues to rise. In 2023, the US Food and Drug Administration [...] Read more.
Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the availability of effective medications and lifestyle interventions, blood pressure control rates remain poor globally, and the prevalence of hypertension continues to rise. In 2023, the US Food and Drug Administration approved renal denervation—a catheter-based procedure that ablates the renal sympathetic nerves—as an adjunctive treatment for patients with uncontrolled or resistant hypertension, defined as blood pressure above goal despite the use of at least three antihypertensive medications, including a diuretic at maximally tolerated doses. Both radiofrequency and ultrasound-based devices are approved for this procedure. However, individual patient responses vary, and further research is needed to clarify long-term efficacy, safety, and optimal patient selection. The number of trained proceduralists and access to facilities is increasing, but multidisciplinary teams and shared decision-making are recommended to ensure appropriate referrals and patient education. In this review, we discuss the pathophysiology of hypertension and approaches to treatment, review the history of renal denervation and the data on which FDA approval was based, detail the safety profile of commercially available devices, and provide a practical, team-based approach to appropriate patient selection. Full article
(This article belongs to the Special Issue Hypertension in Cardiorenal Diseases)
►▼ Show Figures

Figure 1

14 pages, 612 KB  
Review
Hypertension: A Proximal Clinical Signature and Promoter of Early Cardiorenal Disease?
by Maria Bachlitzanaki, Georgios Aletras, Konstantina Papakonstantinopoulou, Nektaria Vasilaki, Eirini Bachlitzanaki, Maria Stratinaki and Charalampos Lydakis
J. CardioRenal Med. 2026, 2(1), 2; https://doi.org/10.3390/jcrm2010002 - 5 Feb 2026
Viewed by 767
Abstract
Hypertension has traditionally been viewed as a hemodynamic disorder leading to cardiac and renal injury; however, growing evidence suggests that, in many individuals, elevated blood pressure is instead the earliest clinical expression of subtle cardiorenal dysfunction. Early abnormalities—such as low-grade albuminuria, increased renal [...] Read more.
Hypertension has traditionally been viewed as a hemodynamic disorder leading to cardiac and renal injury; however, growing evidence suggests that, in many individuals, elevated blood pressure is instead the earliest clinical expression of subtle cardiorenal dysfunction. Early abnormalities—such as low-grade albuminuria, increased renal resistive index, arterial stiffness, and masked or nocturnal hypertension—can appear before estimated glomerular filtration rate decline or elevated office blood pressure, indicating early impairment of pressure–natriuresis, heightened tissue renin–angiotensin–aldosterone system (RAAS) activity, and increased renal microvascular impedance. The aim of this review is to summarize mechanistic, clinical, and phenotypic evidence supporting the concept that hypertension functions as an early biomarker along the cardiorenal continuum. Incorporating vascular and renal biomarkers, ambulatory blood pressure phenotyping, and targeted laboratory indices into routine assessment may identify individuals transitioning from functional disturbances to structural organ damage. These abnormalities reflect a mechanistic triad of arterial stiffening, salt-sensitive RAAS activation, and circadian blood pressure disruption, collectively defining the early cardiorenal–hypertensive phenotype. Viewing hypertension through a cardiorenal lens underscores a critical opportunity for earlier detection and mechanism-oriented intervention, which may modify disease trajectory and prevent progression to overt chronic kidney disease and heart failure. Full article
(This article belongs to the Special Issue Hypertension in Cardiorenal Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop